UAE becomes third country globally to approve Foundayo for type 2 diabetes

Gulf News · Huda Ata · 2026-11-06 14:34 UTC

UAE becomes the third country to approve Foundayo for type 2 diabetes, expanding its use for better blood sugar control and weight management.

Foundayo is a once-daily oral treatment that helps adults control blood sugar levels

Abu Dhabi: The Emirates Drug Establishment (EDE) has approved a new therapeutic use for Foundayo (orforglipron), an oral medication developed by US pharmaceutical company Eli Lilly, to treat type 2 diabetes in adults, making the UAE the third country in the world to authorise the medicine for this purpose, according to the regulator.

The approval expands the use of the drug, which was previously authorised by the EDE for chronic weight management in April 2026, when the UAE became the second country globally to approve it for that indication.

Read the full story at Gulf News · All coverage of this story